
Excited to share our new @EORTC publication in European Urology describing the design of the EORTC 2238 DE-ESCALATE trial. Can intermittent maximal androgen blockade reduce treatment burden while maintaining outcomes in selected men with #mHSPC receiving ADT + ARPI? That's the question we're addressing. 👉 doi.org/10.1016/j.eururo.202… @DeEscalate_EU #ProstateCancer #ClinicalTrials #EUrology






























